Continued use of Atorvostatin in sepsis

A phase II randomised controlled trial in patients on statin therapy who develop sepsis to evaluate the effect of continued atorvastatin use on the incidence of severe sepsis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000756628

Enrollment

150

Registered

2005-11-18

Start date

2006-05-08

Completion date

2008-10-17

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

study completed and the results are now published in the American journal of Respiratory and critical care medicine

Interventions

Atorvostatin as continuation of statin therapy for a 28 day study period ( or until discharge form hospital)

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All patients with sepsis syndrome who are on statin therapy at the time of admisison to hospital are eligable for inclusion.

Exclusion criteria

Pregnancy, acute liver failure or chronic liver disease ( more than Childs B), patients who are moribund and not expected to survive 24 hrs, patients with rhabdomyolysis or myopathy of any cause. Patients in whom any enteral intake will clearly not be possible within 72 hours.

Outcome results